BRD4 and non-small cell lung carcinoma: Here, we found that inhibition of BRD4 enhanced osimertinib sensitivity by suppressing YAP1-mediated APT1 transcription and subsequently disrupting MST1 depalmitoylation and the nuclear translocation of YAP1 in NSCLC, revealing a novel mechanism underlying osimertinib resistance.